Review Compares Diagnostic Strategies for Assessment of Coronary Artery Disease

2023-06-06
AHA会议临床结果
TUESDAY, June 6, 2023 -- Coronary computed tomography angiography (CCTA) is associated with a similar risk for cardiovascular death and myocardial infarction as direct invasive coronary angiography (ICA) for initial assessment of suspected stable coronary artery disease (CAD), according to a review published online June 6 in the Annals of Internal Medicine.
Andrea Zito, M.D., from the Catholic University of the Sacred Heart in Rome, and colleagues compared the effect of clinical management and subsequent health effects of alternative diagnostic strategies for initial assessment of suspected stable CAD. The strongest evidence was available for three comparisons: CCTA versus ICA, CCTA versus exercise electrocardiography (ECG), and CCTA versus stress single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI; four, two, and five trials, respectively).
The researchers found that CCTA was associated with no difference in cardiovascular death and myocardial infarction compared with direct ICA referral, but was associated with less index ICA and index revascularization (relative risks, 0.23 and 0.71, respectively). Compared with exercise ECG and SPECT-MPI, CCTA was associated with a reduction in cardiovascular death and myocardial infarction (relative risks, 0.66 and 0.64, respectively). More index revascularization was seen in association with CCTA versus exercise ECG (relative risk, 1.78), but less downstream testing was observed (relative risk, 0.56).
"This meta-analysis provides comparative evidence of the relative performance of individual diagnostic strategies for the initial assessment of patients with suspected stable CAD," the authors write. "Results' uncertainty calls for further research to better assess the relative performance of each diagnostic strategy."
Abstract/Full Text (subscription or payment may be required)
Posted June 2023
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。